Childhood Cancers Subject of New Law

Publication
Article
OncologyONCOLOGY Vol 14 No 12
Volume 14
Issue 12

At the end of its session, Congress passed a children’s health bill (H.R. 4365) that established a variety of new health programs. One section of the bill authorizes the CDC to study environmental and other risk factors for childhood cancers,

At the end of its session, Congress passed a children’shealth bill (H.R. 4365) that established a variety of new health programs. Onesection of the bill authorizes the CDC to study environmental and other riskfactors for childhood cancers, including skeletal malignancies, leukemias,malignant tumors of the central nervous system, lymphomas, soft-tissue sarcomas,and other malignant neoplasms. In addition to studying those conditions, the CDCwas told to fund projects to improve outcomes among children with those cancersand resulting secondary conditions, such as loss of limbs. The CDC already has aprogram to help states set up cancer registries. The states themselves decidewhat the registries will focus on, and some of them are very narrowly gauged.Thirty-nine states have registries. The CDC gave away $24 million in fiscal year2000 to these state registries. Very few of the states do much with regard tochildhood cancers, and the CDC will ostensibly try to change this. Thejust-passed bill instructs the CDC to set up a national reporting system thatwill involve oncologists, who will have to provide diagnosis and epidemiolgicdata.

Related Videos
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.